Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia

American Journal of Cardiology

Volumn 84, Issue 5, 1999, Pages 519-524

  Peter, Karlheinz ^c   Straub, Andreas ^b   Kohler, Benedikt ^a   Volkmann, Martin ^b   Schwarz, Meike ^b   Kübler, Wolfgang ^b   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CAFFEINE; CITRIC ACID; EDETIC ACID; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PADGEM PROTEIN; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN-TYROSINE-PHOSPHATASE; RECOMBINANT PROTEINS; RECURRENCE; THROMBOCYTOPENIA; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032873921     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00370-7     Document Type: Article

References (15)

1. Lefkovits J., Plow E.F., Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 23:1995;1553-1559.
2. Coller B.S. Platelet GPIIb/IIIa antagonists the first anti-integrin receptor therapeutics . J Clin Invest. 100:1997;S57-S60.
3. Topol E.J., Byzova T.V., Plow E.F. Platelet GP IIb-IIIa blockers. Lancet. 353:1999;227-231.
4. Kereiakes D.J., Essell J.H., Abbotsmith C.W., Broderick T.M., Runyon J.P. Abciximab-associated profound thrombocytopenia therapy with immunoglobulin and platelet transfusion . Am J Cardiol. 78:1996;1161-1163.
5. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation. 95:1997;809-813.
6. Giugliano R.P. Drug-induced thrombocytopenia is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombolysis. 5:1998;191-202.
7. Vorchheimer D.A., Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists the present challenge is safety . Circulation. 97:1998;312-314.
8. 3) inhibitors. Blood. 92:1998;3240-3249.
9. Michelson A.D. Flow cytometry a clinical test of platelet function . Blood. 87:1996;4925-4936.
10. 3 (platelet GP IIb-IIIa). Cell. 65:1991;409-416.
11. Miyamoto S., Akiyama S.K., Yamada K.M. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science. 267:1995;883-885.
12. 2+ signaling. Blood. 92:1998;3675-3683.
13. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
14. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem. 266:1991;17106-17111.
15. Nakatani S., Hato T., Minamoto Y., Fujita S. Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5. Thromb Haemost. 76:1996;1030-1037.